Myra Waiman
Direktor/Vorstandsmitglied bei iosBio Ltd.
Profil
Myra Waiman is a Non-Executive Director at iosBio Ltd.
and a former Non-Executive Director at Novacta Biosystems Ltd.
She completed her undergraduate degree at Imperial College London.
Aktive Positionen von Myra Waiman
Unternehmen | Position | Beginn |
---|---|---|
iosBio Ltd.
iosBio Ltd. Packaged SoftwareTechnology Services iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Myra Waiman
Unternehmen | Position | Ende |
---|---|---|
Novacta Biosystems Ltd.
Novacta Biosystems Ltd. BiotechnologyHealth Technology Novacta Biosystems Ltd. discovered and developed drugs for treatment of bacterial infections. Its products included lantibiotic/bacteriocin variants, as well as a development candidate for the treatment of C. difficile infection. The company was founded by John Michael Dawson on February 14, 2015 and was headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ausbildung von Myra Waiman
Imperial College London | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Novacta Biosystems Ltd.
Novacta Biosystems Ltd. BiotechnologyHealth Technology Novacta Biosystems Ltd. discovered and developed drugs for treatment of bacterial infections. Its products included lantibiotic/bacteriocin variants, as well as a development candidate for the treatment of C. difficile infection. The company was founded by John Michael Dawson on February 14, 2015 and was headquartered in London, the United Kingdom. | Health Technology |
iosBio Ltd.
iosBio Ltd. Packaged SoftwareTechnology Services iosBio Ltd. is a British UK-based biotechnology company that specializes in developing next-generation vaccines that can be administered orally. The company was founded by Jeffrey Drew and is based in Burgess Hill, UK. The company's proprietary orapro™ thermal stabilization technology enables the oral administration of thermally stable, non-replicating viral vectors that can be delivered sublingually via the gastrointestinal tract and other routes. iosBio is developing vaccines designed to stimulate mucosal, systemic, and T-cell immune responses, providing robust immunity to a number of infectious diseases, including COVID-19, Zika, and influenza. | Technology Services |